engages in the discovery, development, and commercialization of anti-infectives, antibiotics, and vaccines for the prevention and treatment of serious infectious diseases. It focuses on products for use in defense against biological warfare agents, such as smallpox and arenaviruses/hemorrhagic fevers. Its products include ST-246, an orally administered anti-viral drug targets smallpox virus; and ST-294, which demonstrates antiviral activity in cell culture assays against arenavirus pathogens. The companyÂ’s antiviral products, which are in various stages of development ranging from initial research and screening to Phase I human clinical trials include Smallpox, New World Arenavirus, Old World Arenavirus, Filovirus (Ebola & Marburg), Dengue Fever virus, and Bunyavirus; and antibiotic products, including Gram-positive, Gram-negative, and broad spectrum antibiotic technologies for addressing drug-resistant bacteria and hospital-acquired infections. SIGA Technologies has license agreements and collaborative research arrangements with National Institutes of Health, United States Army Medical Research and Material Command, United States Air Force, United States Army Medical Research Acquisition Activity, Saint Louis University, and TransTech Pharma, Inc. The company was founded in 1995 and is headquartered in New York, New York.
$6.5099 (04/15/09)
